Navigating the Medicare open enrollment period with a rare disease
What to keep in mind as you select your plan
Written by |
Every October, my mailbox fills up with glossy Medicare mailers promising $0 premiums, free gym memberships, and grocery cards. And every October, most of them go straight into the recycling bin. It’s not because those perks are bad, but because none of them answer the one question that matters to me: Will this plan cover the care that keeps my eosinophilic granulomatosis with polyangiitis quiet?
On Oct. 30, the Eosinophilic & Rare Disease Cooperative (ERDC) hosted our Medicare Open Enrollment for Rare Disease livestream. I’ve walked through this process several times, for myself and alongside our community, and truth be told, it still makes my head spin. Medicare isn’t easy for anyone. But when you live with a rare disease, the stakes are higher and the fine print matters so much more.
Last year, I wrote about choosing the right Medicare plan when you live with a rare disease, and so much of that still holds. But a few things have been sitting heavy on my heart this season, so here’s what I have to share as I sip my morning coffee:
Start with your doctors: If you see a local doctor and a specialist outside your area, as so many of us do, look hard at HMO plans. An HMO may not cover the vasculitis specialist two hours away, the one who actually understands your disease. Before you fall in love with a plan, make sure every doctor on your team is in network. All of them.
Then check your medications, every single one: Formularies change every year, and they vary wildly from plan to plan. If a medication doesn’t show up as covered, don’t panic and don’t assume. Call the plan directly and ask whether it’s on the formulary but requires prior authorization or step therapy. Those are very different answers from “not covered.”
And call the manufacturer. I can’t say this enough. Drug companies have terrific support programs built to help people work through insurance hurdles. I suspect they are underutilized. They know these plans inside and out.
Do the math: Premiums get all the attention, but they’re only one piece. Look at deductibles, copays, and Part B coinsurance. Then plug in what you already know: your infusions, your specialist visits, your monthly prescriptions. A plan with a higher premium can easily cost you less over the year — or not. It has actually felt empowering to me to be able to add up and plan as best I can.
Look at the star ratings: If you’re choosing Medicare Advantage, I generally recommend sticking with plans rated 4 stars or higher. Those ratings reflect things you’ll lean on when something goes sideways, like customer service, appeals, and care coordination. It is something I consider at least.
Why we’re fighting step therapy
During the livestream, I talked about something that worries me, and my crystal ball says it is going to get harder for us. Step therapy and “fail first” policies are creeping into our rare disease reality. These rules force us to try, and fail, cheaper treatments before an insurer will cover the one our doctor prescribed. For a disease that can damage our lungs, nerves, heart, and kidneys, failing first isn’t a paperwork issue. It can mean permanent harm.
It’s the same reason I urged the U.S. Food and Drug Administration to keep Tavneos (avacopan) available, even though I can’t take it myself. People with rare diseases cannot afford to lose a single path to treatment.
I’m grateful to Amgen and AstraZeneca for supporting ERDC’s public policy work. We couldn’t push on these issues the way we do without them.
You can watch the full livestream and see the slides on our website. For a deeper dive into how Medicare works, type “Medicare” into the search bar in the Learn section of our site to find all of our videos on the topic.
Open enrollment ends Dec. 7. It is worth your time to set aside an afternoon, grab a cup of tea, and check your doctors, your meds, and your numbers.
Note: ANCA Vasculitis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of ANCA Vasculitis News or its parent company, Bionews, and are intended to spark discussion about issues pertaining to ANCA vasculitis.
Leave a comment
Fill in the required fields to post. Your email address will not be published.